KODIAK SCIENCES INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
KODIAK SCIENCES INC. (KOD) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $8.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $3.51M, a 173.85% increase year-over-year.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $4.56M, a 93.55% increase year-over-year.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$2.00K, a 100.49% decline year-over-year.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $5.64M, a 398.59% increase year-over-year.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $9.27M.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$7.37M.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$12.91M.
- KODIAK SCIENCES INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$2.25M, a 116.62% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $8.07M 10-Q · filed 2026-08-13 | $8.06M derived: sum of 3 quarters · filed 2026-08-13 | $13.70M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $4.56M 10-Q · filed 2026-05-07 | $4.56M derived: sum of 2 quarters · filed 2026-05-07 | $10.20M derived: sum of 3 quarters · filed 2026-05-07 | $11.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.64M derived: sum of 2 quarters · filed 2026-03-31 | $6.92M derived: sum of 3 quarters · filed 2026-08-13 | $9.27M 10-K · filed 2026-03-31 |
| 2025-09-30 | $5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.92M derived: sum of 2 quarters · filed 2026-08-13 | $9.28M 10-Q · filed 2025-11-13 | $9.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.64M 10-Q · filed 2026-08-13 | $4.04M derived: sum of 3 quarters · filed 2026-08-13 | $5.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.35M 10-Q · filed 2026-05-07 | $2.76M derived: sum of 2 quarters · filed 2026-05-07 | $3.89M derived: sum of 3 quarters · filed 2026-05-07 | $570.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.54M derived: sum of 2 quarters · filed 2026-03-31 | -$1.78M derived: sum of 3 quarters · filed 2026-03-31 | -$7.37M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.19M derived: sum of 2 quarters · filed 2025-11-13 | -$7.78M 10-Q · filed 2025-11-13 | -$12.42M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | -$3.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$8.91M 10-Q · filed 2025-08-13 | -$13.55M derived: sum of 3 quarters · filed 2026-03-31 | -$17.54M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | -$5.59M 10-Q · filed 2025-05-14 | -$10.23M derived: sum of 2 quarters · filed 2026-03-31 | -$14.22M derived: sum of 3 quarters · filed 2026-03-31 | -$13.12M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | -$4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$8.63M derived: sum of 2 quarters · filed 2026-03-31 | -$7.54M derived: sum of 3 quarters · filed 2026-03-31 | -$12.91M 10-K · filed 2026-03-31 |
| 2023-09-30 | -$3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.89M derived: sum of 2 quarters · filed 2024-11-14 | -$8.26M 10-Q · filed 2024-11-14 | -$15.91M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.27M 10-Q · filed 2024-08-14 | -$11.92M derived: sum of 3 quarters · filed 2025-03-27 | -$8.06M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | -$5.37M 10-Q · filed 2024-05-15 | -$13.02M derived: sum of 2 quarters · filed 2025-03-27 | -$9.16M derived: sum of 3 quarters · filed 2025-03-27 | -$21.31M derived: sum of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | -$7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.79M derived: sum of 2 quarters · filed 2025-03-27 | -$15.94M derived: sum of 3 quarters · filed 2025-03-27 | -$2.25M 10-K · filed 2025-03-27 |
| 2022-09-30 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$8.29M derived: sum of 2 quarters · filed 2023-11-14 | $5.40M 10-Q · filed 2023-11-14 | $8.37M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | -$12.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.54M 10-Q · filed 2023-08-14 | $4.51M derived: sum of 3 quarters · filed 2024-03-28 | -$403.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $13.70M 10-Q · filed 2023-05-15 | $16.66M derived: sum of 2 quarters · filed 2024-03-28 | $11.75M derived: sum of 3 quarters · filed 2024-03-28 | $24.00M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | $2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$1.95M derived: sum of 2 quarters · filed 2024-03-28 | $10.31M derived: sum of 3 quarters · filed 2024-03-28 | $13.51M 10-K · filed 2024-03-28 |
| 2021-09-30 | -$4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $7.34M derived: sum of 2 quarters · filed 2022-11-09 | $10.55M 10-Q · filed 2022-11-09 | $14.73M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $12.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $15.46M 10-Q · filed 2022-08-09 | $19.64M derived: sum of 3 quarters · filed 2023-03-28 | $24.59M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $3.21M 10-Q · filed 2022-05-10 | $7.39M derived: sum of 2 quarters · filed 2023-03-28 | $12.33M derived: sum of 3 quarters · filed 2023-03-28 | $14.72M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $9.13M derived: sum of 2 quarters · filed 2023-03-28 | $11.52M derived: sum of 3 quarters · filed 2023-03-28 | $11.75M 10-K · filed 2023-03-28 |
| 2020-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.34M derived: sum of 2 quarters · filed 2021-11-09 | $7.57M 10-Q · filed 2021-11-09 | $11.02M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $2.62M 10-Q · filed 2021-08-09 | $6.07M derived: sum of 3 quarters · filed 2022-03-01 | $8.01M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $228.00K 10-Q · filed 2021-05-10 | $3.68M derived: sum of 2 quarters · filed 2022-03-01 | $5.62M derived: sum of 3 quarters · filed 2022-03-01 | $6.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.39M derived: sum of 2 quarters · filed 2022-03-01 | $6.05M derived: sum of 3 quarters · filed 2022-03-01 | $4.93M 10-K · filed 2022-03-01 |
| 2019-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.59M derived: sum of 2 quarters · filed 2020-11-09 | $1.48M 10-Q · filed 2020-11-09 | $2.89M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $655.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$459.00K 10-Q · filed 2020-08-10 | $947.00K derived: sum of 3 quarters · filed 2021-03-01 | $1.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$1.11M 10-Q · filed 2020-05-11 | $292.00K derived: sum of 2 quarters · filed 2021-03-01 | $866.00K derived: sum of 3 quarters · filed 2021-03-01 | $1.28M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.98M derived: sum of 2 quarters · filed 2021-03-01 | $2.40M derived: sum of 3 quarters · filed 2021-03-01 | -$2.10M 10-K · filed 2021-03-01 |
| 2018-09-30 | $574.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $991.00K derived: sum of 2 quarters · filed 2019-11-12 | -$3.51M 10-Q · filed 2019-11-12 | $864.00K derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$4.08M 10-Q · filed 2019-08-14 | $290.00K derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | -$4.50M 10-Q · filed 2019-05-15 | -$127.00K derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $4.33M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | -$45.00K 10-Q · filed 2018-11-16 | |||
| 2016-12-31 | $242.00K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |